Obstetric cholestasis — or ICP — causes intense itching in late pregnancy and requires careful monitoring. This guide gives you honest, specific information: what your bile acid numbers actually mean, how UDCA works, what the evidence says about risk, and how induction timing is decided.
🍃 Open full guide in WiseMama — freeObstetric cholestasis — intrahepatic cholestasis of pregnancy (ICP) — is a liver condition that occurs only during pregnancy. Its most distinctive feature is intense itching, typically on the hands and feet, usually without a rash. It affects around 1 in 140 pregnancies in the UK, though rates are significantly higher in women of South Asian, Chilean, and Scandinavian heritage. It almost always develops in the third trimester and resolves completely after birth — usually within days.
Under normal circumstances, the liver produces bile acids to aid fat digestion, then reabsorbs and recycles most of them. During pregnancy, the hormones oestrogen and progesterone progressively impair the liver's ability to transport bile acids out of liver cells and into bile ducts. In women with ICP, this impairment is more pronounced — bile acids accumulate in liver cells, spill into the bloodstream, and deposit in skin tissue, which is what causes the itching.
The liver is not being permanently damaged by this process, and bile acid levels return to normal after delivery. What matters clinically is the effect of elevated bile acids on the baby — and that picture is more nuanced than either "it's fine" or "it's dangerous" suggests.
What it is: Impaired liver bile acid transport during pregnancy
Main symptom: Intense itching, hands and feet, worse at night — usually without rash
When it appears: Almost always in the third trimester
Affects: ~1 in 140 UK pregnancies (higher in South Asian, Chilean, Scandinavian women)
Treatment: Ursodeoxycholic acid (UDCA)
After birth: Resolves completely, usually within days
The itching of obstetric cholestasis is distinctive, and people who have experienced it consistently describe it as unlike any itch they have had before — relentless, deep, and worse at night when nothing can be done about it. Sleep deprivation from itching is extremely common. It can affect the whole body but typically starts on the palms and soles, and often feels like it comes from inside the skin rather than on the surface.
There is usually no rash associated with ICP itself, though scratching can cause marks and broken skin. If you have a visible rash alongside the itching, other causes should be considered — particularly PEP (polymorphic eruption of pregnancy), which causes significant itching with a rash but is not associated with fetal risk.
Some women with ICP develop additional symptoms beyond itching — pale or greasy stools (from impaired fat absorption), dark urine, mild jaundice (yellowing of skin or whites of eyes), or discomfort in the upper right abdomen where the liver sits. These are less common but always worth reporting to your midwife or GP, as they suggest more significant liver involvement and may influence management.
Contact your midwife or GP and describe your symptoms. Ask specifically for liver function tests (LFTs) and serum bile acid testing — by name. Some clinicians will offer antihistamines without testing first, particularly for generalised itching earlier in pregnancy. This is worth gently pushing back on: antihistamines treat the symptom but not the condition, and the diagnosis of ICP requires specific blood tests. You are entitled to ask for them.
I mentioned the itching at my 34-week appointment and was told it was probably just stretching skin. Two weeks later, after I pushed for the blood test, I was diagnosed with ICP with a bile acid level of 68. I wish I'd pushed sooner.
ICP is diagnosed through blood tests. Understanding what the tests measure — and what the numbers mean — is one of the most useful things you can do, because the specific bile acid level is the most important driver of your management.
Serum bile acids are the primary diagnostic test. Levels above 10 µmol/L in pregnancy are generally considered diagnostic of ICP. This test is not always automatically included in routine blood panels — you may need to request it specifically.
Liver function tests (LFTs) measure liver enzyme activity (primarily ALT and AST). These can be elevated in ICP independently of bile acids, or alongside them. Some women have elevated LFTs with normal bile acids; some have elevated bile acids with near-normal LFTs. Both situations require attention, but bile acids are the primary risk indicator.
The management of ICP is substantially shaped by bile acid level, which is why knowing your specific number — not just "raised" — is important:
It also matters whether levels are stable, improving on UDCA, or rising. A bile acid level of 45 µmol/L that is falling in response to UDCA is a different clinical picture to one rising from 40 to 75 µmol/L over two weeks.
Once diagnosed, most women with ICP are moved to consultant-led care and have bile acid and LFT blood tests repeated every 1–2 weeks — more frequently if levels are moderate to severe or rising. Fetal monitoring includes awareness of reduced fetal movements (always report a change immediately), and in most units, fortnightly cardiotocography (CTG — a continuous trace of the baby's heart rate) from diagnosis onwards. Some units also offer additional growth ultrasounds, as ICP is associated with a slightly higher rate of spontaneous preterm birth.
Ask specifically: what is my current bile acid level? How does it compare to last time — is it stable, rising, or improving? At what level would my management change? What would trigger a change in induction timing for me? Concrete numbers anchor the experience considerably more reliably than general reassurance.
If itching suddenly and significantly worsens — which can indicate a rapid rise in bile acids — or if you notice reduced fetal movements, develop jaundice, or have upper right abdominal pain, contact your maternity unit immediately. Do not wait for your next scheduled appointment.
There is no treatment that cures ICP — it is a pregnancy-specific condition that resolves after delivery. But there is a well-established treatment that reliably reduces bile acid levels and improves symptoms for most women.
UDCA — sometimes known by the brand name Ursofalk — is the standard treatment for ICP in the UK and internationally. It is a naturally occurring bile acid that, taken in supplementary doses, alters the composition of bile in the liver and bloodstream, reduces overall serum bile acid levels, and appears to improve placental function. Most women notice improvement in itching within one to two weeks of starting it, and many see a meaningful reduction in bile acid levels at the next blood test.
UDCA is prescribed once ICP is diagnosed, in doses tailored to body weight — typically between 500mg and 2000mg daily in divided doses. The dose may be adjusted upward if the initial response is insufficient. It is considered safe in pregnancy and has a long track record in ICP management.
For a minority of women — particularly those with moderate to severe ICP — UDCA alone may not adequately control bile acid levels. In these cases, the dose may be increased, or rifampicin may be considered as an add-on therapy in specialist centres. If your bile acid levels continue to rise despite UDCA, or your symptoms are not improving, raise this explicitly with your consultant. "My levels are not responding adequately to treatment" is an important clinical conversation to have proactively rather than waiting to be told.
ICP can impair fat absorption by reducing bile flow into the gut, which affects absorption of fat-soluble vitamins including vitamin K — important for normal blood clotting in both mother and baby. Some units offer oral vitamin K supplementation, particularly for women with jaundice or more severe disease. Ask your team whether this is appropriate for you.
Nothing fully controls the itch of ICP except UDCA and delivery — but several things can take the edge off, particularly at night:
Sleep deprivation from itching is real and cumulative. Treating the sleep disruption directly is a legitimate and important part of managing ICP, not an afterthought.
This is the section most women with ICP most want to read, because the risk picture is frequently either understated — "it's fine, just itchy" — or overstated — "it's so dangerous" — and neither serves anyone well. Understanding what the evidence actually shows allows you to ask better questions and make more genuinely informed decisions.
The mechanism by which elevated bile acids increase fetal risk is not completely understood, but the most widely accepted model is as follows: bile acids cross the placenta and enter the fetal circulation. Research has shown that high concentrations of bile acids can cause bradycardia — slowing of the heart rate — in fetal cardiac tissue, potentially contributing to sudden intrauterine death. Bile acids also appear to impair placental function, reducing the efficiency with which oxygen and nutrients reach the baby. This is why CTG monitoring is used in ICP: it can detect fetal heart rate abnormalities that may precede deterioration.
The research on ICP and stillbirth has been significantly refined in recent years. Earlier studies suggested elevated stillbirth risk across all severity levels, which drove the blanket "induce at 37 weeks" guidance that many women still receive from units that haven't updated their protocols.
The PITCHES trial — a large, well-powered UK randomised controlled trial — and subsequent meta-analyses substantially revised this picture. The current RCOG guidance, updated in 2022, reflects this evidence:
The background UK stillbirth rate is approximately 4 per 1,000 births. In mild to moderate ICP managed appropriately, current evidence suggests this is not significantly elevated. In severe ICP (≥100 µmol/L), the risk is meaningfully higher — which is exactly why management is more active at that threshold. Understanding which category you are in is therefore the most important single piece of information to have.
The timing of birth is the central clinical conversation in ICP, and it is worth being well-prepared for. Understanding the current guidance, what induction for ICP looks like in practice, and what your rights are in this conversation removes much of the uncertainty.
The RCOG's 2022 guidance recommends individualising induction timing based on bile acid level:
These are recommendations, not mandates. The decision is yours, made with your clinical team in light of your specific bile acid levels, their trajectory, and your individual circumstances. Some women with mild, stable ICP choose expectant management beyond 40 weeks after a full informed conversation. Others with moderate ICP choose earlier induction for peace of mind. Both are valid informed choices.
For most women with ICP, induction follows standard protocols. If the cervix is unfavourable, it will be ripened first — usually with a prostaglandin pessary (Propess) or balloon catheter. Once the cervix is ripe, amniotomy (breaking the waters) is performed, and a Syntocinon (synthetic oxytocin) drip is used if contractions don't establish spontaneously. None of this is specific to ICP — it is standard induction practice.
What is standard specifically for ICP is continuous CTG monitoring throughout labour, so that any fetal heart rate abnormalities can be detected promptly. This is precautionary — not because problems are expected, but because prompt detection matters if they occur. Continuous CTG does not require lying still: wireless telemetry systems are widely available, and movement, birthing balls, and various positions are all compatible with continuous monitoring. It is worth confirming with your unit what monitoring options they have.
ICP is not in itself an indication for caesarean section. Vaginal birth — including induction of labour — is entirely appropriate for women with ICP. Mode of birth depends on individual obstetric factors, not on the diagnosis of ICP alone. If you have a preference regarding mode of birth, this is a conversation to have with your consultant rather than assuming ICP determines the answer.
Itching typically resolves within 48 hours of delivery — one of the first and most noticeable changes after birth for women with ICP. Bile acids and LFTs normalise within days to a few weeks. A repeat blood test at 10–14 days postnatal is recommended to confirm resolution. If abnormalities persist beyond 6–8 weeks, further investigation for underlying liver conditions is warranted, as ICP occasionally reveals a pre-existing liver susceptibility.
Two questions almost everyone with ICP asks: will it happen again, and what does it mean for my health in the longer term?
ICP has a high recurrence rate — approximately 45–90% in subsequent pregnancies. This is not inevitable, but it is the most likely outcome if you have further pregnancies. If you plan future pregnancies, tell your booking midwife early so bile acid monitoring can begin promptly. Do not wait for itching to return before requesting bile acid testing — the monitoring should begin in the second trimester even in the absence of symptoms.
Combined hormonal contraceptives — the combined pill, the patch, the vaginal ring — can trigger a cholestasis-like liver response in women who have had ICP. Some women with a history of ICP find they cannot tolerate the combined pill. Progesterone-only methods (the mini-pill, the hormonal coil, the implant) are generally better tolerated. Discuss this with your GP before starting contraception postnatally.
ICP appears to indicate an underlying hepatic susceptibility that has broader implications beyond pregnancy. Women who have had ICP have a higher lifetime risk of gallstones, and a modestly elevated risk of non-alcoholic fatty liver disease and, in some studies, cardiovascular disease. These associations are statistical rather than certainties — having had ICP does not mean you will develop these conditions — but they are worth being aware of for future health monitoring.
There is no specific surveillance protocol for all ICP survivors, but mentioning your history to your GP is worthwhile so it can be noted in your records and factored into future health checks. Some GPs will monitor liver function annually — this is a reasonable discussion to have.
ICP Support (icpsupport.org) is the UK charity specifically for women with ICP. Their resources are clinically reviewed and consistently updated to reflect current evidence — including the PITCHES trial findings — and their helpline connects you with others who have been through the same experience. They are the most reliable single source of additional information beyond your clinical team.
Obstetric cholestasis arrives late in pregnancy, at a point when most people are already physically uncomfortable, emotionally stretched, and counting down the weeks. It adds a new layer of anxiety onto an already demanding time — and the anxiety it brings is not irrational. It is a rational response to a situation of genuine clinical uncertainty.
The experience of waiting for bile acid results, monitoring fetal movements with heightened vigilance, navigating conversations about induction timing, and itching relentlessly through every night — while also trying to prepare for a baby and function in daily life — is genuinely hard. Naming that is not catastrophising. It is accurate.
Most women with ICP describe knowledge as the most effective anxiety-management tool available. Not reassurance — "I'm sure it'll be fine" — but actual numbers. Knowing that your bile acid level is 28 µmol/L and stable, rather than knowing only that you "have ICP," is a fundamentally different emotional position. Ask for the numbers. Ask what they mean. Ask what the trajectory is. You are entitled to this information and entitled to be treated as someone who can understand it.
ICP Support's online community connects women currently experiencing ICP with those who have been through it — often the most useful support is not clinical information but hearing "I know exactly what that 3am itch feels like, and I know what helped me."
ICP-related anxiety can become clinically significant — particularly for women with a previous pregnancy loss, a family history of stillbirth, or whose bile acid levels are in the moderate to severe range. If anxiety is significantly affecting your sleep (beyond what the itching alone explains), relationships, or ability to function, tell your midwife. A referral to the perinatal mental health team is appropriate and available. You do not need to manage this level of anxiety alone.
Knowing the number was the thing that helped most. Not "you have ICP" — but "your bile acids are 34, which is mild, and we'll test again in two weeks." That gave me something concrete to hold onto. I wish I'd been given the number from the very start.